##  [Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness](/us-en/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness-0 "Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness") 

  Nov 10, 2017